FDA warning companies not to sell unapproved cannabidiol products

被引：0

作者：

机构：

来源：

Reactions Weekly | 2021年 / 1850卷 / 1期

关键词：

D O I：

10.1007/s40278-021-93810-z

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：5 / 5

相关论文

共 50 条

[41] Warning letters: Warning letters demand stop to unapproved ergotamine manufacture and distribution
Rios, Maribel
Pharmaceutical Technology, 2007, 31 (04)
[42] Companies - Huntsman to sell packaging
Westervelt, R
CHEMICAL WEEK, 1999, 161 (47) : 13 - 13
[43] FDA rosiglitazone warning
Kuehn, Bridget M.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 298 (24): : 2858 - 2858
[44] FDA VARICELLA WARNING
TINKELMAN, DG
PEDIATRICS, 1992, 90 (03) : 479 - 480
[45] FDA Warning for Etravirine
不详
JOURNAL OF DRUGS IN DERMATOLOGY, 2009, 8 (11) : 1050 - 1050
[46] FDA Azithromycin Warning
不详
MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2013, 55 (1413): : 28 - 28
[47] High Costs of FDA Approval for Formerly Unapproved Marketed Drugs
Hakim, Aaron
Gupta, Ravi
Ross, Joseph S.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (22): : 2181 - 2182
[48] Displaying investigational and unapproved medical devices according to FDA policy
Shapiro, Jeffrey K.
Medical Device and Diagnostic Industry, 1997, 19 (10):
[49] FDA requires boxed warning for all immediate-release opioid products
Thompson, Cheryl A.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2016, 73 (09) : E114 - E115
[50] Analysis of FDA Warning Letters Issued to Indian Pharmaceutical and Medical Device Companies: A Retrospective Study
Bablani, Shray
Janodia, Manthan D.
THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2019,

← 1 2 3 4 5 →